OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP monoclonal antibodies preventive treatment: A real‐world evidence study
Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 7, pp. 2378-2382
Closed Access | Times Cited: 26
Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 7, pp. 2378-2382
Closed Access | Times Cited: 26
Showing 1-25 of 26 citing articles:
CGRP-targeted medication in chronic migraine - systematic review
Renato Oliveira, Raquel Gil‐Gouveia, Francesca Puledda
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 19
Renato Oliveira, Raquel Gil‐Gouveia, Francesca Puledda
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 19
New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy
Mi Ji Lee, Mohammad Al‐Mahdi Al‐Karagholi, Uwe Reuter
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 28
Mi Ji Lee, Mohammad Al‐Mahdi Al‐Karagholi, Uwe Reuter
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 28
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 11
Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 11
CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention
Edoardo Caronna, Alicia Alpuente, Marta Torres‐Ferrús, et al.
Handbook of clinical neurology (2024), pp. 107-124
Closed Access | Times Cited: 10
Edoardo Caronna, Alicia Alpuente, Marta Torres‐Ferrús, et al.
Handbook of clinical neurology (2024), pp. 107-124
Closed Access | Times Cited: 10
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients
Soonwook Kwon, Young‐Eun Gil, Mi Ji Lee
Cephalalgia (2022) Vol. 42, Iss. 8, pp. 705-714
Closed Access | Times Cited: 26
Soonwook Kwon, Young‐Eun Gil, Mi Ji Lee
Cephalalgia (2022) Vol. 42, Iss. 8, pp. 705-714
Closed Access | Times Cited: 26
OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Toxins (2022) Vol. 14, Iss. 12, pp. 847-847
Open Access | Times Cited: 24
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Toxins (2022) Vol. 14, Iss. 12, pp. 847-847
Open Access | Times Cited: 24
Combining treatments for migraine prophylaxis: the state-of-the-art
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
Nicolas Vandenbussche, Karolina Pisarek, Koen Paemeleire
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 12
Nicolas Vandenbussche, Karolina Pisarek, Koen Paemeleire
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 12
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management
Patricia Pozo‐Rosich, Alicia Alpuente, Stephen D. Silberstein, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 9, pp. 555-568
Closed Access | Times Cited: 3
Patricia Pozo‐Rosich, Alicia Alpuente, Stephen D. Silberstein, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 9, pp. 555-568
Closed Access | Times Cited: 3
VESTIBULAR MIGRAINE: ONABOTULINUM TOXIN EFFECTIVITY, PROSPECTIVE-RANDOMIZED STUDY
Reyhan Sürmeli, Mehmet Surmeli, Ayşe Destînâ Yalçın, et al.
Clinical Neurology and Neurosurgery (2025), pp. 108949-108949
Open Access
Reyhan Sürmeli, Mehmet Surmeli, Ayşe Destînâ Yalçın, et al.
Clinical Neurology and Neurosurgery (2025), pp. 108949-108949
Open Access
Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study
Jason C. Ray, Linda J. Dalic, Josephine Baker, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000547-e000547
Open Access | Times Cited: 2
Jason C. Ray, Linda J. Dalic, Josephine Baker, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000547-e000547
Open Access | Times Cited: 2
Comparative effectiveness and tolerability of calcitonin gene‐related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real‐world study in Taiwan
Yen‐Feng Wang, Fu‐Chi Yang, Lu‐An Chen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 9
Open Access | Times Cited: 2
Yen‐Feng Wang, Fu‐Chi Yang, Lu‐An Chen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 9
Open Access | Times Cited: 2
CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies
Yen‐Feng Wang, Shuu‐Jiun Wang
Current Pain and Headache Reports (2022) Vol. 26, Iss. 7, pp. 543-554
Closed Access | Times Cited: 8
Yen‐Feng Wang, Shuu‐Jiun Wang
Current Pain and Headache Reports (2022) Vol. 26, Iss. 7, pp. 543-554
Closed Access | Times Cited: 8
Nummular headache responsive to anti‐calcitonin gene‐related peptide monoclonal antibodies in a patient with migraine
A. López-Bravo, Antonio Oliveros‐Cid, Ane Mínguez‐Olaondo, et al.
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 8, pp. 1063-1066
Closed Access | Times Cited: 6
A. López-Bravo, Antonio Oliveros‐Cid, Ane Mínguez‐Olaondo, et al.
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 8, pp. 1063-1066
Closed Access | Times Cited: 6
Dual therapy with Erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: A retrospective cohort study
Alex Jaimes, Andrea Gómez, Olga Pajares, et al.
Pain Practice (2022) Vol. 23, Iss. 4, pp. 349-358
Closed Access | Times Cited: 6
Alex Jaimes, Andrea Gómez, Olga Pajares, et al.
Pain Practice (2022) Vol. 23, Iss. 4, pp. 349-358
Closed Access | Times Cited: 6
Combining onabotulinumtoxin A with a CGRP antagonist for chronic migraine prophylaxis: where do we stand?
Lanfranco Pellesi
Frontiers in Pain Research (2023) Vol. 4
Open Access | Times Cited: 3
Lanfranco Pellesi
Frontiers in Pain Research (2023) Vol. 4
Open Access | Times Cited: 3
Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine
R Mahon, Pamela Vo, Katharina Pannagl, et al.
Current Medical Research and Opinion (2022) Vol. 39, Iss. 1, pp. 105-112
Closed Access | Times Cited: 3
R Mahon, Pamela Vo, Katharina Pannagl, et al.
Current Medical Research and Opinion (2022) Vol. 39, Iss. 1, pp. 105-112
Closed Access | Times Cited: 3
Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions
Slobodan Јаnkovic, Snežana V. Janković
European Journal of Drug Metabolism and Pharmacokinetics (2024) Vol. 49, Iss. 3, pp. 263-275
Closed Access
Slobodan Јаnkovic, Snežana V. Janković
European Journal of Drug Metabolism and Pharmacokinetics (2024) Vol. 49, Iss. 3, pp. 263-275
Closed Access
Exploring Nonresponse to Botulinum Toxin in Aesthetics: A Review of Key Trigger Factors and Effective Management Strategies (Preprint)
George Kroumpouzos, Fernando Silikovich
(2024)
Closed Access
George Kroumpouzos, Fernando Silikovich
(2024)
Closed Access
Exploring Nonresponse to Botulinum Toxin in Aesthetics: A Narrative Review of Key Trigger Factors and Effective Management Strategies (Preprint)
George Kroumpouzos, Fernando Silikovich
JMIR Dermatology (2024)
Open Access
George Kroumpouzos, Fernando Silikovich
JMIR Dermatology (2024)
Open Access
(CGRP) Monocloncal antibodies
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Recomendaciones de la Asociación Colombiana de Neurología para el uso de anticuerpos monoclonales antiCGRP en la profilaxis de migraña
Oscar Enrique Pradilla-Vesga, José David Martinez, Mauricio Rueda-Sánchez, et al.
Acta neurológica colombiana (2022) Vol. 38, Iss. 1 Supl 1, pp. 1-22
Open Access | Times Cited: 1
Oscar Enrique Pradilla-Vesga, José David Martinez, Mauricio Rueda-Sánchez, et al.
Acta neurológica colombiana (2022) Vol. 38, Iss. 1 Supl 1, pp. 1-22
Open Access | Times Cited: 1
The Role of Step Therapy in the Treatment of Migraine
Leon S. Moskatel, Niushen Zhang
Current Pain and Headache Reports (2023) Vol. 27, Iss. 10, pp. 571-577
Closed Access
Leon S. Moskatel, Niushen Zhang
Current Pain and Headache Reports (2023) Vol. 27, Iss. 10, pp. 571-577
Closed Access
